333 related articles for article (PubMed ID: 11798469)
1. Structural and biologic characterization of pegylated recombinant IFN-alpha2b.
Grace M; Youngster S; Gitlin G; Sydor W; Xie L; Westreich L; Jacobs S; Brassard D; Bausch J; Bordens R
J Interferon Cytokine Res; 2001 Dec; 21(12):1103-15. PubMed ID: 11798469
[TBL] [Abstract][Full Text] [Related]
2. Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway.
Grace MJ; Lee S; Bradshaw S; Chapman J; Spond J; Cox S; Delorenzo M; Brassard D; Wylie D; Cannon-Carlson S; Cullen C; Indelicato S; Voloch M; Bordens R
J Biol Chem; 2005 Feb; 280(8):6327-36. PubMed ID: 15596441
[TBL] [Abstract][Full Text] [Related]
3. PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative.
Ramon J; Saez V; Baez R; Aldana R; Hardy E
Pharm Res; 2005 Aug; 22(8):1374-86. PubMed ID: 16078148
[TBL] [Abstract][Full Text] [Related]
4. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications.
Wang YS; Youngster S; Grace M; Bausch J; Bordens R; Wyss DF
Adv Drug Deliv Rev; 2002 Jun; 54(4):547-70. PubMed ID: 12052714
[TBL] [Abstract][Full Text] [Related]
5. Regulation of gene expression by pegylated IFN-alpha2b and IFN-alpha2b in human peripheral blood mononuclear cells.
Brassard DL; Delorenzo MM; Cox S; Leaman DW; Sun Y; Ding W; Gavor S; Spond J; Goodsaid F; Bordens R; Grace MJ
J Interferon Cytokine Res; 2004 Aug; 24(8):455-69. PubMed ID: 15320959
[TBL] [Abstract][Full Text] [Related]
6. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b.
Youngster S; Wang YS; Grace M; Bausch J; Bordens R; Wyss DF
Curr Pharm Des; 2002; 8(24):2139-57. PubMed ID: 12369859
[TBL] [Abstract][Full Text] [Related]
7. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS).
Foser S; Schacher A; Weyer KA; Brugger D; Dietel E; Marti S; Schreitmüller T
Protein Expr Purif; 2003 Jul; 30(1):78-87. PubMed ID: 12821324
[TBL] [Abstract][Full Text] [Related]
8. A long-acting, highly potent interferon alpha-2 conjugate created using site-specific PEGylation.
Rosendahl MS; Doherty DH; Smith DJ; Carlson SJ; Chlipala EA; Cox GN
Bioconjug Chem; 2005; 16(1):200-7. PubMed ID: 15656592
[TBL] [Abstract][Full Text] [Related]
9. Pegylation and Cell Based Bioassay of Human Interferon-α2b Along its Docking Studies and Effect on Plasma Half-Life.
Shahzadi SK; Qadir MA; Mahmood N; Ahmed M
Protein Pept Lett; 2020; 27(3):219-224. PubMed ID: 31612813
[TBL] [Abstract][Full Text] [Related]
10. A new method to produce monoPEGylated dimeric cytokines shown with human interferon-α2b.
Chang CH; Rossi EA; Cardillo TM; Nordstrom DL; McBride WJ; Goldenberg DM
Bioconjug Chem; 2009 Oct; 20(10):1899-907. PubMed ID: 19736932
[TBL] [Abstract][Full Text] [Related]
11. Biologic activity of polyethylene glycol12000-interferon-alpha2b compared with interferon-alpha2b: gene modulatory and antigrowth effects in tumor cells.
Vyas K; Brassard DL; DeLorenzo MM; Sun Y; Grace MJ; Borden EC; Leaman DW
J Immunother; 2003; 26(3):202-11. PubMed ID: 12806274
[TBL] [Abstract][Full Text] [Related]
12. Effect of pegylation on self-association of IFN-α2b.
Mohs A; Ambrogelly A; Yang X; Haverick M; Cheung JK; Narasimhan C; Shameem M
Mol Pharm; 2014 Jan; 11(1):158-63. PubMed ID: 24266549
[TBL] [Abstract][Full Text] [Related]
13. Identification of the major positional isomer of pegylated interferon alpha-2b.
Wang YS; Youngster S; Bausch J; Zhang R; McNemar C; Wyss DF
Biochemistry; 2000 Sep; 39(35):10634-40. PubMed ID: 10978146
[TBL] [Abstract][Full Text] [Related]
14. Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity.
Monkarsh SP; Ma Y; Aglione A; Bailon P; Ciolek D; DeBarbieri B; Graves MC; Hollfelder K; Michel H; Palleroni A; Porter JE; Russoman E; Roy S; Pan YC
Anal Biochem; 1997 May; 247(2):434-40. PubMed ID: 9177709
[TBL] [Abstract][Full Text] [Related]
15. Pegylation of IFN-alpha and antiviral activity.
Boulestin A; Kamar N; Sandres-Sauné K; Alric L; Vinel JP; Rostaing L; Izopet J
J Interferon Cytokine Res; 2006 Dec; 26(12):849-53. PubMed ID: 17238827
[TBL] [Abstract][Full Text] [Related]
16. Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway.
Grace MJ; Cutler D
Antivir Chem Chemother; 2004 Nov; 15(6):287-97. PubMed ID: 15646642
[TBL] [Abstract][Full Text] [Related]
17. [Obtaining and characteristics of domestic preparation interferon alpha-2b with prolonged effect].
Pokholenko IaA; Porubleva LV; Dubeĭ IIa; Rebriev AV; Sutugina LP; Gromovoĭ TIu; Pokrovskiĭ VA; Obolenskaia MIu; Chernykh SI
Ukr Biokhim Zh (1999); 2008; 80(6):92-100. PubMed ID: 19351063
[TBL] [Abstract][Full Text] [Related]
18. Effects of pegylated interferon α2b on metastasis of hepatocellular carcinoma.
Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T
J Surg Res; 2012 Jan; 172(1):95-101. PubMed ID: 20851413
[TBL] [Abstract][Full Text] [Related]
19. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
[TBL] [Abstract][Full Text] [Related]
20. Highly glycosylated human alpha interferon: An insight into a new therapeutic candidate.
Ceaglio N; Etcheverrigaray M; Conradt HS; Grammel N; Kratje R; Oggero M
J Biotechnol; 2010 Mar; 146(1-2):74-83. PubMed ID: 20067809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]